Jim Glasheen

Jim Glasheen is a prominent figure in the biotechnology industry with extensive experience in leadership roles. He was the Co-Founder, President, CEO (2018-2019), and board member (2018-2020) at Atalanta Therapeutics. Currently, Jim is associated with Clade Therapeutics, where he has demonstrated his expertise in strategic direction and team alignment.1

Career Highlights

Clade Therapeutics: Jim Glasheen has been actively involved with Clade Therapeutics. In February 2024, he oversaw a challenging period for the company, which included a reduction in force.2 However, more recently, in April 2024, he announced the acquisition of Clade Therapeutics by Century Therapeutics, marking a significant development for the company.3

Previous Acquisitions: Jim has experience with corporate acquisitions. In October 2023, he announced Clade Therapeutics' acquisition of Gadeta, which expanded Clade's pipeline and broadened its capabilities.4

Other Roles: Prior to his current position, Jim served as the executive vice chancellor for innovation and business development at UMass Medical School.6

Personal Life

Jim Glasheen is also a family man. In August 2023, he shared a proud moment when his daughter Sierra secured her first job at the Royal Ballet in London.5

Jim Glasheen's career trajectory showcases his expertise in strategic leadership, business development, and innovation in the biotechnology sector. His experience spans from startups to established institutions, demonstrating his versatility and impact in the field.